杂交瘤细胞培养的优化

根据杂交瘤细胞培养中单克隆抗体生产的动力学原理,采用灌注培养方式、添加醋酸钾和丰富营养物培养的途径,对反应器放大培养过程进行了优化。每天灌注l／2反应器工作体积,与分批培养相比,细胞密度由4 5×10⁵／ml提高到l1×10⁵／ml,单抗浓度由19mg／L提高到28mg/L;添加1g／L醋酸钾,细胞密度基本保持不变．但单抗浓度增加到38μg／ml;用丰富营养物培养后,细胞密度和单抗浓度分别进一步提高到42×10⁵／ml和94mg/L。抗B型红细胞单抗的血凝滴度,由分批培养的1：32．最终提高到l：256     

厚叶景天组织传感器的研究

利用厚叶景天的叶和茎组织作为生物催化材料,分别同二氧化碳气敏电极和氨气敏电极组合,研制了L－精氨酸传感器及,L－赖氨酸传感器。两种传感器的线性范围分别为1.0×10^-4 1.O×10^-3mol/L和8．0×10^-5—3.0×10^-3mol/L．检测下限分别为3．2×10^-5mol／L和2.2×10^-5mol/L,响应斜率分别为42.2mV／dec和41．4mv／dec。考察了两种传感器的回收率．结果表明,L－精氨酸传感器和L－赖氨酸传感器的回收率平均值分别为98．6％和101.6％,标准偏差分别为4.6％和4.0％。     

抗人IL-6单克隆抗体的制备及鉴定

用基因重组人IL-6免疫Balb/c小鼠,采用小鼠杂交瘤技术,筛选克隆到分泌抗人重组IL-6单克隆抗体的杂交瘤细胞株,并对其中2H₂、 1D₂ 和4B₄瘤细胞株进行了鉴定.其抗体类别均为IgG,亚类分别为IgG1和IgG2a.用多种细胞因子和无关蛋白的鉴别试验结果证实它们均特异地识别rhIL-6.免疫转染结果显示,该单抗识别分子质量为21 ku的IL-6单一条带.IL-6单克隆抗体的亲和常数K_aff= 1.62×10⁹ (mol/L)^-1.     

在中空纤维细胞培养系统内用无血清培养基生产单克隆抗体

用1640SFM无血清培养基在VF－2中空纤维细胞培养系统内培养7E8杂交瘤细胞,最大活细胞密度为2．34×10⁶／ml,该活细胞密度分别是转瓶培养和静态瓶培养结果的3．7倍和2．2倍。培养42天共收获7E8细胞培养液10000ml,其单克隆抗体(简称单抗)的ELIsA效价为1:20000左右,该效价是转瓶培养和静态瓶培养结果的25倍。ID。0mI培养液经50％饱和硫酸铵盐析和sephadex G-200柱层析提纯,获纯化单抗IgG 51．82mg。该系统平均每天生产单抗12．3mg。研究结果表明;在中空纤维培养系统内用无血清培养基培养杂交瘤细胞的方法可望用于体外大规模生产单抗。     

抗黄曲霉毒素B1单克隆抗体的制备及特性

用杂交瘤技术制备了5株产生抗黄曲霉毒紊B₁单克隆抗体的杂交瘤细胞株。对其中之一AFB1－2H8进行了较系统的研究。AFB1一2H8属IgC3。纯化腹水抗体效价约5×10⁶。ELISA检测标准毒素的线性范围为0．5～50ng／ml。最低检出量为0．01ng／ml。该单抗与参试的其它黄曲霉代谢物的交叉反应系数为0～0．21,该抗体有较大的应用价值。     

人血液血管细胞生成素的胎肝免疫印记检测

目的：制备一种新蛋白——人血液血管细胞生成素（hemangiopoietin,HAPO）的单克隆抗体,检测其在胎肝中的表达。方法：杂交瘤方法制备抗HAP0的单克隆抗体;非竞争酶联免疫吸附实验测定抗体的相对亲和力;蛋白G亲和层析纯化腹水中的抗体,免疫印记方法检测胎肝中天然HAPO的表达：结果：所获单抗分别为IgG1及IgM,其轻链均为κ。三株IgG1亚类单抗的相对亲和力分别为3．06×10^9mol／L,6．07×10^8mol／L和1．71×10^10 mol／L。亲和纯化后抗体的纯度达99％以上：胎肝中在蛋白水平上可以检测到HAP0的表达,天然HAPO的分子量接近于重组HAPO的分子量。结论：人胚胎肝组织中在蛋白水平上可以检测到HAPO的表达.     

微囊化杂交瘤细胞培养的基础应用研究

本文探讨了海藻酸钠的结构组分对微囊强度的重要作用。提出了微囊化批量生产中估算活细胞的方法以及影响满囊比的主要因素等a制备微囊的成功率达到95％以上,满载率可达95％。微囊化杂交瘤细胞在静态培养6—10天后,细胞浓度为8．8×10⁶～2．1×10⁷ceIl／ml微囊。单抗浓度为379μg／m1微囊。微囊化产物经SDS电泳呈现一条或两条蛋白带,表明单抗纯度较高。     

用基因克隆大肠杆菌发光体系测定长链脂肪醛

利用基因克隆大肠杆菌发光体系分别测试了五种长链脂肪醛和脂肪酸。结果表明:可在几分钟内测出癸醛,正辛醛和十二烷醛的极限浓度分别为1×10^-14mol/L、1×10^-12mol/L和1×10^-9mol/L,是一种灵敏、快速的测试方法。     

2.5次微分伏安法对生物样品中丙二醛的测定

以0.1mol/L NH₄Cl溶液为介质, 用2.5次微分伏安法测定了丙二醛, 线性范围为1.0×10^-6至1.0×10^-3 mol/L, 检测限达1.0×10^-7 mol/L. 并测定了细胞培养液介质中新生SD大鼠心室肌细胞样品中的丙二醛.     

再生丝素固定的酶标免疫传感器的研究

所研究的酶标免疫传感器是采用再生丝素将待测抗原 (兔IgG)固定在石墨电极表面 ,选用抗体 (山羊抗兔IgG HRP)与其识别结合。利用H₂O₂ 将抗原抗体结合的电位响应信号放大采用直接电位法检测IgG的浓度。该传感器测定IgG的最低浓度可达 1.2×10^-10 mol/L ,标准曲线的线形范围在4.1×10^-7～1.2×10^-10 mol/L ,回归方程为: E=-1049+721g[IgG],响应时间为 15s。通过电泳的方法加速抗原抗体的识别结合 ,反应时间由原来的 90min缩短到 3 0min。这种以固定化抗原结合酶标抗体量的多少作为检测抗原标准的新型酶标免疫传感器 ,在临床检测、环境监测、HLA个人身份鉴定等领域都有着广阔的应用前景。     

Transient expression of hepatitis B virus surface antigen (HBsAg) and human erythropoietin (hEPO) genes in milk after direct introduction into ewe

Ｅｘｐｒｅｓｓｉｏｎｏｆｍｉｌｋｐｒｏｔｅｉｎｇｅｎｅｓｉｓｉｎｖｏｌｖｅｄｉｎａｈｕｇｅｎｅｔｗｏｒｋｏｆｒｅｇｕｌａｔｏｒｙｃｉｒｃｕｉｔｓｗｈｉｃｈａｒｅｌｉｎｋｅｄｔｏｔｈｅｉｎｔａｃｔｄｅｖｅｌｏｐｉｎｇｍａｍｍａｒｙｇｌａｎｄ,ａｎｄｈｏｍｅｏｓｔａｓｉｓｄｕｒｉｎｇｐｕｂｅｒｔｙ,ｐｒｅｇｎａｎｃｙ,ｌａｃｔａｔｉｏｎａｎｄｉｎｖｏｌｕｔｉｏｎ.Ａｎａｌｙｓｉｓｏｆｐｕｔａｔｉｖｅｒｅｇｕｌａｔｏｒｙｅｌｅｍｅｎｔｓａｎｄｈｙｂｒｉｄｇｅｎｅｉｎｔｉｓｓｕｅｃｕｌｔｕｒｅｓｙｓｔｅｍｓ…     

Recombinant human erythropoietin produced in milk of transgenic pigs

We have developed a line of transgenic swine harboring recombinant human erythropoietin through microinjection into fertilized one cell pig zygotes. Milk from generations F1 and F2 transgenic females was analyzed, and hEPO was detected in milk from all lactating females at concentrations of approximately 877.9+/-92.8 IU/1 ml. The amino acid sequence of rhEPO protein in the transgenic pig milk matched that of commercial rhEPO produced from cultured animal cells. In addition, an F-36 cell line, which proliferates in the presence of hEPO or commercial EPO, was induced to synthesize erythroid by extracts from tg sow milk. This study provides evidence that production of purified rhEPO from transgenic pig milk is a potentially valuable technology, and can be used as a cost-effective alternative in clinical applications as well as providing other clinical advantages.     

Expression of functionally active sialylated human erythropoietin in plants

Recombinant human erythropoietin (rhEPO), a glycohormone, is one of the leading biopharmaceutical products. The production of rhEPO is currently restricted to mammalian cell expression systems because of rhEPO's highly complex glycosylation pattern, which is a major determinant for drug-efficacy. Here we evaluate the ability of plants to produce different glycoforms of rhEPO. cDNA constructs were delivered to Nicotiana benthamiana (N. benthamiana) and transiently expressed by a viral based expression system. Expression levels up to 85 mg rhEPO/kg fresh leaf material were achieved. Moreover, co-expression of rhEPO with six mammalian genes required for in planta protein sialylation resulted in the synthesis of rhEPO decorated mainly with bisialylated N-glycans (NaNa), the most abundant glycoform of circulating hEPO in patients with anemia. A newly established peptide tag (ELDKWA) fused to hEPO was particularly well-suited for purification of the recombinant hormone based on immunoaffinity. Subsequent lectin chromatography allowed enrichment of exclusively sialylated rhEPO. All plant-derived glycoforms exhibited high biological activity as determined by a cell-based receptor-binding assay. The generation of rhEPO carrying largely homogeneous glycosylation profiles (GnGnXF, GnGn, and NaNa) will facilitate further investigation of functionalities with potential implications for medical applications.     

Gene therapy for rat renal anemia with implantation of erythropoietin-transgenic myoblasts

To investigate whether an erythropoietin (EPO) gene-based therapy could serve as an alternative to the repeated injection of rhEPO in treatment to renal anemia, the genetically modified myoblasts of rats, named Myo/ EPO, were implanted through intramuscular injection to model rats with renal anemia. The hemoglobin (Hb) and hematocrit (HCT) of the rats increased from (92.5 ±3.0) g/L and 0.29±0.04 to the peak values of (103.8 ±5.0) g/L and 0. 32 ±0. 04 respectively 14 d after implantation, and sustained the pre-implantation level for 90 d. Otherwise, the control rats implanted with Myo/X, which carried the parent retroviral vector, gradually became severe in anemia. The PCR detection for hEPO cDNA in the rat muscle adjacent to injection sites indicated that the Myo/EPO cells survived for a long period in the muscle of rats. The results primarily demonstrate that myoblast gene transfer of EPO is effective for the treatment of rat renal anemia.     

Determination of norfloxacin using a terbium-sensitized electrogenerated chemiluminescence method.

A simple electrogenerated chemiluminescence (ECL) analysis method for the determination of norfloxacin (NFLX) is reported. It is based on ECL produced by Na(2)SO(3), which is sensitized by the Tb-NFLX complex. The relative ECL intensity of the Tb(3+)-NFLX-Na(2)SO(3) system is proportional to the amount of NFLX. The optimized experimental conditions were investigated. The linear range and detection limit for NFLX were 1.0 x 10(-10)-8.0 x 10(-7) mol/L and 2.8 x 10(-11) mol/L, respectively. This method was successfully applied to the determination of NFLX in a capsule. NFLX in urine can be directly detected without pretreatment or separation.     

甲状旁腺素、表皮生长因子及维生素A酸对UMR106细胞EGF受体的调节作用

本文研究了EGF、PTH和RA对UMR106细胞EGF受体的调节作用。结果显示PTH能上调EGF的受体,UMR106细胞经bPTH(1-34)处理3天,EGF受体的相对结合率与对照比较提高了40.3％,每个细胞的EGF受体数目从7.22×10~3增加到1.44×10~4,Kd从2.02×10~(-11)增加到3.68×10~(-11)mol/L。而RA则能下调EGF受体,以RA处理3天,EGF受体数目从7.22×10~3下降到4.28×10~3,Kd则从2.02×10~(-11)增加到4.17×10~(-11)mol/L。提示PTH和RA可能通过调变其EGF受体而分别起到正性和负性生长调节作用。     

Gene therapy for rat renal anemia with implantation of erythropoietin-transgenic myoblasts

To investigate whether an erythropoietin (EPO) gene-based therapy could serve as an alternative to the repeated injection of rhEPO in treatment to renal anemia, the genetically modified myoblasts of rats, named Myo/ EPO, were implanted through intramuscular injection to model rats with renal anemia. The hemoglobin (Hb) and hematocrit (HCT) of the rats increased from (92. 5±3.0) g/L and 0.29 ±0.04 to the peak values of (103.8 ±5.0) g/L and 0. 32 ±0. 04 respectively 14 d after implantation, and sustained the pre-implantation level for 90 d. Otherwise, the control rats implanted with Myo/X, which carried the parent retroviral vector, gradually became severe in anemia. The PCR detection for hEPO cDNA in the rat muscle adjacent to injection sites indicated that the Myo/EPO cells survived for a long period in the muscle of rats. The results primarily demonstrate that myoblast gene transfer of EPO is effective for the treatment of rat renal anemia.     

Determination of daunomycin at a novel COOH/indium tin oxide ion implantation-modified electrode

A novel COOH+ ion implantation-modified indium tin oxide (COOH/ITO) electrode was prepared for the first time and applied for determination of daunomycin (or daunorubicin [DNR]). The electrode showed higher catalytic activity than bare ITO electrode with good reproducibility and stability. The determination condition of linear voltammetry was optimized. A calibration curve was obtained over the range 2.0 x 10(-7) to 5.0 x 10(-6)mol/L, with a correlation coefficient of 0.9909 and a limit of detection of 1.0 x 10(-7)mol/L. The selectivity of the electrode was illustrated by determination of DNR in samples prepared of urine. X-ray photoelectron spectroscopy (XPS) analysis results showed that the implanted COOH+ maintained characteristics of organic group -COOH. A field emission-scanning electron microscope (FSEM) result showed that the implanted surface caused defects and partial dislocations and formed many active centers.     

Binding of [99mTc]chondroitin sulfate to scavenger receptors on human chondrocytes as compared to binding of oxidized [125I]LDL on human macrophages

Chondroitin sulfate (CS) used for treatment of osteoarthritis exerts distinct effects on human articular chondrocytes in vitro. We performed a binding analysis with 99mTc-labeled CS (Condrosulf, a commercial CS preparation containing calcium stearate) and cultured human chondrocytes in order to evaluate the presence of specific receptors. Saturation binding at 37 degrees C for 2 h revealed the presence of high-affinity binding sites for CS with a Kd of 2.3 x 10(-9) mol/L and a Bmax of 5.0 x 10(8). Extensive dialysis of Chondrosulf led to a decrease of the binding affinity by 52.5 +/- 19.5% and of the number of CS binding sites/cell by 62.0 +/- 14.0%, demonstrating that the additive present in the Condrosulf preparation enhances CS binding. The nature of the binding site is not yet known but evidence exists in the literature that the scavenger receptor CD36, thoroughly investigated on macrophages, is also found on chondrocytes and might be involved in CS binding. Therefore, we undertook a comparative binding study with human monocytes and labelled LDL and oxidized LDL, the latter being a postulated atherogenic agent in atherosclerosis. For [125I]-LDL binding we found a Kd of 0.45 x 10(-8) mol/L and a Bmax of 0.14 x 10(6) on quiescent monocytes and for [125I]-(ox)LDL binding a Kd of 1.8 x 10(-8) mol/L and a Bmax of 1.3 x 10(6) using LPS-activated monocytes. These data are comparable to the binding affinity found for lipoprotein-proteoglycan-complexes and hence are an indication but not a proof that CD36 is involved in CS binding to human chondrocytes.     

Generation of transgenic silkworms for production of erythropoietin in Bombyx mori

There have been many attempts to generate various essential proteins using transformed E. coli systems. However, prokaryote systems are not equipped with the protein maturation mechanisms necessary to generate eukaryotic proteins. In this sense, among the eukaryotes, silkworms have major merits in overcoming the difficulties. Such protein maturation mechanisms are available in silkworms. In this study, a transgenic silkworm producing rhEPO in the cocoon was generated and purified. Specifically, we constructed a transgenic silkworm using a vector system that could be controlled to the next generation. To accomplish this, we microinjected the system into eggs laid during the preblastoderm stage. The rhEPO was then purified from transgenic silkworm cocoons using a Con A affinity column. The biological activity of rhEPO isolated from the cocoon of transgenic silkworms was then assessed in a cell culture system using an EPO-dependent cell line, F-36E. Next, PCR analysis was used to demonstrate that stable gene expression can occur in the embryos of the silkworm, Bombyx. mori. Transgenic silkworms were then selected and observed to ensure that the transgenic silkworm was maintained and transmitted to their progeny. The rhEPO was subsequently purified from the transgenic silkworm cocoon and the electrophoretic pattern of the purified rhEPO revealed a protein band with a molecular weight of approximately 20 kDa. A total of 3 mg of rhEPO was eluted from 10 g of cocoons. The proliferation of F36E cells for 25 ng/ml rhEPO was 1.32, while the proliferation for 2.5 IU/ml hEPO was 1.32. The proliferation of these cells could be induced by commercial hEPO, as well as by rhEPO from transgenic silkworm cocoons. An in vivo test of mice treated with rhEPO revealed relatively high RBC values when compared to normal mice. These results indicated that purified glycosylated EPO from transgenic silkworms had biological activities. Overall, the transgenic silkworm technique will be very useful for the large scale production of proteins for diagnostic and therapeutic purposes.